Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue while reporting ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an implantable device, after clinical trial data showed the treatment did not ...

Vertex is also developing a version called VX-264 in which the cells are encapsulated in a protective device designed to protect them from rejection by the immune system. A phase 1/2 trial of VX ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion.

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals.

Even worse was the fact that adjusted earnings excluded a $379 million asset impairment charge that stemmed from the decision not to advance Vertex's VX-264 program for patients with type 1 diabetes.

The company said it would not be advancing further in VX-264 clinical trials. Vertex plans to conduct further analyses, including of explanted devices. Vertex Pharmaceuticals shares gained 0.5% to ...

Intangible asset impairment charge of $379.0 million associated with VX-264 (the “cells plus device” program) in patients with type 1 diabetes, which will not be advancing further in clinical ...

In addition, it also had a $379.0 million intangible asset impairment charge associated with its experimental diabetes treatment VX-264, which it won't be advancing for additional clinical ...